高级搜索
维拉帕米增强丝裂霉素抗癌作用的实验研究[J]. 肿瘤防治研究, 2001, 28(04): 278-280. DOI: 10.3971/j.issn.1000-8578.1773
引用本文: 维拉帕米增强丝裂霉素抗癌作用的实验研究[J]. 肿瘤防治研究, 2001, 28(04): 278-280. DOI: 10.3971/j.issn.1000-8578.1773
Experiment study on enhancement of antitumor effect of mitomycin Cbyverapamil in human Cervical Cancer[J]. Cancer Research on Prevention and Treatment, 2001, 28(04): 278-280. DOI: 10.3971/j.issn.1000-8578.1773
Citation: Experiment study on enhancement of antitumor effect of mitomycin Cbyverapamil in human Cervical Cancer[J]. Cancer Research on Prevention and Treatment, 2001, 28(04): 278-280. DOI: 10.3971/j.issn.1000-8578.1773

维拉帕米增强丝裂霉素抗癌作用的实验研究

Experiment study on enhancement of antitumor effect of mitomycin Cbyverapamil in human Cervical Cancer

  • 摘要: 目的 探讨维拉帕米 ( Verapamil,VER)对丝裂霉素 ( mitomycin,MMC)耐药逆转作用。方法 利用人宫颈癌 Hela和耐药亚系 Hela/MMC细胞, 建立人宫颈癌裸鼠异种移植耐药模型。初步研究了 VER对 MMC体内外增效作用。结果 无毒剂量的 VER( 1~ 3mg/L)可显著增加MMC的细胞毒作用且可基本克服 Hela/MMC细胞对 MMC5.0 2倍耐药 ;并可增加 MMC对宫颈癌细胞 DNA合成的抑制 ;同时可提高 MMC对荷瘤裸鼠 Hela/MMC移植瘤的抑制率 ( P<0 .0 1 )。结论 无毒剂量的 VER体内外能基本逆转 Hela/MMC细胞对 MMC的耐药性.

     

    Abstract: Objective To determine the reversion of mitomycin(MMC)resistance by verapamil (VER)in vitro and in vivo. Methods A xenografted mitomycin resistant mice model of cervical cancer was devoleped.The reversion of mitomycin of resistance by VER was detected for human cervical cancar cell(hela)and its resistant subline Hela/MMC in vitro and in vivo. Results nontoxin doses of VER might enhance the cytotoxicity of MMC in Hela and Hela/MMC,could result in almost complete or partial reversion of MMC resisistance of Hei...

     

/

返回文章
返回